title: Renal dopaminergic mechanisms in renal parenchymal diseases, hypertension, and heart failure.
abstract: The recovery of renal function in renal transplant recipients is accompanied by an enhanced ability to synthesize dopamine (DA), which may contribute to maintain sodium homeostasis. Patients suffering from chronic renal parenchymal disease, a well-recognized form of salt sensitive (SS) hypertension, have a reduced ability to produce DA that correlates well with deterioration of renal function. In patients afflicted with IgA nephropathy, but normal renal function, urinary excretion of DA correlated positively with BP responses to changes from 200 to 20 mmol/day salt intake. In black salt resistant (SR) normotensives (NT) and SR hypertensives, under low salt intake (40 mmol/day), but not SS-NT and SS-HT, the saline infusion induced increments of DA and DOPAC urinary excretion correlated significantly with increments of sodium urinary excretion and sodium fractional excretion. Patients afflicted with heart failure (HF) have a reduced delivery of L-DOPA to the kidney, accompanied by an increase in DA/L-DOPA urinary ratios. This suggests that HF patients have an increased ability to take up or decarboxylate L-DOPA. Sodium restriction resulted in a significant decrease in urinary L-DOPA, DA and DOPAC in HF patients, suggesting that the system responds to sodium. It is concluded that activity of renal dopaminergic system may be altered in SS subjects, despite the level of their BP, and an enhanced delivery of L-DOPA to the kidney may be beneficial in edema formation states.
authors.affiliation: Institute of Pharmacology and Therapeutics, Faculty of Medicine, Porto, Portugal.
authors.forename: P
authors.initials: P
authors.lastname: Soares-da-Silva
authors.forename: M
authors.initials: M
authors.lastname: Pestana
authors.forename: A
authors.initials: A
authors.lastname: Ferreira
authors.forename: A
authors.initials: A
authors.lastname: Damasceno
authors.forename: J
authors.initials: J
authors.lastname: Polónia
authors.forename: M
authors.initials: M
authors.lastname: Cerqueira-Gomes
mesh_terms: D015102:3,4-Dihydroxyphenylacetic Acid / Q000652:urine; D000818:Animals; D004298:Dopamine / Q000502:physiology*; D006333:Heart Failure / Q000378:metabolism*; D006439:Hemodynamics / Q000502:physiology; D006801:Humans; D006977:Hypertension, Renal / Q000378:metabolism*; D007674:Kidney Diseases / Q000378:metabolism* / Q000601:surgery; D016030:Kidney Transplantation / Q000502:physiology; D007980:Levodopa / Q000378:metabolism; D009399:Nephrons / Q000378:metabolism; D017447:Receptors, Dopamine D1 / Q000378:metabolism; D012964:Sodium / Q000097:blood / Q000652:urine
chemical_list: D017447:Receptors, Dopamine D1; D015102:3,4-Dihydroxyphenylacetic Acid; D007980:Levodopa; D012964:Sodium; D004298:Dopamine